CL2020003169A1 - Métodos de uso de cd24 para prevenir y tratar la recaída de la leucemia - Google Patents

Métodos de uso de cd24 para prevenir y tratar la recaída de la leucemia

Info

Publication number
CL2020003169A1
CL2020003169A1 CL2020003169A CL2020003169A CL2020003169A1 CL 2020003169 A1 CL2020003169 A1 CL 2020003169A1 CL 2020003169 A CL2020003169 A CL 2020003169A CL 2020003169 A CL2020003169 A CL 2020003169A CL 2020003169 A1 CL2020003169 A1 CL 2020003169A1
Authority
CL
Chile
Prior art keywords
prevent
leukemia
methods
relapse
treat relapse
Prior art date
Application number
CL2020003169A
Other languages
English (en)
Inventor
Yang Liu
Pan Zheng
Martin Devenport
Original Assignee
Oncoimmune Inc
Univ Maryland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncoimmune Inc, Univ Maryland filed Critical Oncoimmune Inc
Publication of CL2020003169A1 publication Critical patent/CL2020003169A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/02—Medicinal preparations containing materials or reaction products thereof with undetermined constitution from inanimate materials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001129—Molecules with a "CD" designation not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4208—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
    • C07K16/4241—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/528—CH4 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Oncology (AREA)
  • Transplantation (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención describe el uso de la proteína CD24 para prevenir y tratar la recaída del cáncer en un sujeto. La presente invención también describe el uso de la proteína CD24 para reducir la actividad de las células madre del cáncer
CL2020003169A 2018-06-04 2020-12-04 Métodos de uso de cd24 para prevenir y tratar la recaída de la leucemia CL2020003169A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862680218P 2018-06-04 2018-06-04
US201862739719P 2018-10-01 2018-10-01
US201862739742P 2018-10-01 2018-10-01

Publications (1)

Publication Number Publication Date
CL2020003169A1 true CL2020003169A1 (es) 2021-06-11

Family

ID=68770596

Family Applications (2)

Application Number Title Priority Date Filing Date
CL2020003168A CL2020003168A1 (es) 2018-06-04 2020-12-04 Métodos de uso de cd24 para prevenir y tratar la enfermedad de injerto contra huésped y la mucositis
CL2020003169A CL2020003169A1 (es) 2018-06-04 2020-12-04 Métodos de uso de cd24 para prevenir y tratar la recaída de la leucemia

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CL2020003168A CL2020003168A1 (es) 2018-06-04 2020-12-04 Métodos de uso de cd24 para prevenir y tratar la enfermedad de injerto contra huésped y la mucositis

Country Status (15)

Country Link
US (2) US20210228680A1 (es)
EP (2) EP3802583A4 (es)
JP (2) JP2021527056A (es)
KR (2) KR20210021317A (es)
CN (2) CN112512640A (es)
AU (2) AU2019282530A1 (es)
BR (2) BR112020024683A2 (es)
CA (2) CA3102374A1 (es)
CL (2) CL2020003168A1 (es)
IL (2) IL279205A (es)
MA (2) MA52810A (es)
MX (2) MX2020013100A (es)
SG (2) SG11202011963UA (es)
TW (2) TW202015753A (es)
WO (2) WO2019236472A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3102374A1 (en) * 2018-06-04 2019-12-12 Oncoimmune, Inc. Methods of use of cd24 for the prevention and treatment of leukemia relapse
US20230108492A1 (en) * 2020-02-10 2023-04-06 Oncoimmune, Inc. Methods of use of soluble cd24 for treating viral pneumonia
US20250257117A1 (en) * 2022-04-20 2025-08-14 OncoC4, Inc. Mutant cd24 proteins and uses thereof for prophylaxis and treatment of cancer

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4554101A (en) 1981-01-09 1985-11-19 New York Blood Center, Inc. Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity
CA2705353C (en) * 2007-11-14 2017-07-25 The Medical Research, Infrastructure, And Health Services Fund Of The Tel Aviv Medical Center Methods of treating cancer using anti cd24 antibodies
US20130231464A1 (en) * 2010-04-28 2013-09-05 Oncolmmune, Inc. Methods of use of soluble cd24 for therapy of rheumatoid arthritis
NZ603196A (en) * 2010-04-28 2014-07-25 Oncolmmune Inc Methods of use of soluble cd24 for therapy of rheumatoid arthritis
CN102250828B (zh) * 2010-11-10 2014-11-05 北京大学 Cd24及cd24抗体的新用途
WO2013158959A1 (en) * 2012-04-19 2013-10-24 Tarix Pharmaceuticals Ltd. Compositions and methods for treatment of graft-versus-host disease
CN107207597A (zh) * 2014-11-06 2017-09-26 儿研所儿童医学中心 用于癌症和自身免疫疾病的免疫疗法
AU2016258084B2 (en) * 2015-05-07 2020-01-30 Oncoimmune, Inc. Use of CD24 for lowering low-density lipoprotein cholesterol levels
CA3012466A1 (en) 2016-02-02 2017-08-10 Oncoimmune, Inc. Use of cd24 proteins for treating leptin-deficient conditions
CA3102374A1 (en) * 2018-06-04 2019-12-12 Oncoimmune, Inc. Methods of use of cd24 for the prevention and treatment of leukemia relapse
US20230157955A1 (en) * 2020-01-08 2023-05-25 Puretech Lyt, Inc. Vesicle compositions for oral delivery

Also Published As

Publication number Publication date
MA52810A (fr) 2021-04-14
AU2019282044A1 (en) 2021-01-07
EP3801773A4 (en) 2022-03-16
CN112512640A (zh) 2021-03-16
TW202012015A (zh) 2020-04-01
SG11202011963UA (en) 2020-12-30
CA3102374A1 (en) 2019-12-12
EP3801773A1 (en) 2021-04-14
BR112020024659A2 (pt) 2021-03-09
WO2019236472A1 (en) 2019-12-12
US20210228680A1 (en) 2021-07-29
KR20210021317A (ko) 2021-02-25
IL279204A (en) 2021-01-31
CL2020003168A1 (es) 2021-06-11
KR20210018294A (ko) 2021-02-17
JP2021527066A (ja) 2021-10-11
MA52811A (fr) 2022-03-16
AU2019282530A1 (en) 2021-01-07
CA3102372A1 (en) 2019-12-12
JP2021527056A (ja) 2021-10-11
EP3802583A1 (en) 2021-04-14
TW202015753A (zh) 2020-05-01
EP3802583A4 (en) 2022-03-16
US11911441B2 (en) 2024-02-27
CN112752766A (zh) 2021-05-04
BR112020024683A2 (pt) 2021-03-09
MX2020013100A (es) 2021-02-17
MX2020013103A (es) 2021-05-12
WO2019236474A1 (en) 2019-12-12
SG11202011964SA (en) 2020-12-30
IL279205A (en) 2021-01-31
US20210268061A1 (en) 2021-09-02

Similar Documents

Publication Publication Date Title
CL2019001874A1 (es) Inhibidores de tgfß1 isoforma-específicos contexto-permisivos y uso de los mismos.
CO2021001912A2 (es) Composiciones anti-cd112r y métodos
CO2020015255A2 (es) Métodos y composiciones para tratar el cáncer
CY1123290T1 (el) Ενωσεις και μεθοδοι χρησης
CL2024002093A1 (es) Anticuerpos anti-cd73.
ECSP22038978A (es) INHIBICIÓN DE INTEGRINA ALFA4ß7 HUMANA
MX2021016054A (es) Analogos sinteticos de las ecteinascidinas y su uso como agentes antitumorales.
CO2018010458A2 (es) Composiciones y anticuerpos anti-tim-3
CL2021001260A1 (es) Anticuerpos anti-sirpa humanizados
EA201991214A1 (ru) Антитела против pd-1 и их композиции
MX2020012091A (es) Composiciones anti-cd24 y usos de las mismas.
MX2020004801A (es) Polipeptidos de fusion biespecificos y sus metodos de uso.
MX2018005315A (es) Composiciones y metodos para el tratamiento del cancer.
CL2019002323A1 (es) Anticuerpo dirigido a il-13ra2 y su uso.
MX2022007994A (es) Derivados de arilciclohexilamina y su uso en el tratamiento de trastornos psiquiátricos.
MX2017010919A (es) Proteina de union il-18 (il-18bp) y anticuerpos en enfermedades inflamatorias.
JOP20190285A1 (ar) استخدام الجسم المضاد لمضاد cd70 argx-110 في معالجة سرطان الدم النخاعي الحاد
MX2019001672A (es) Composiciones de poxvirus quiméricos y usos de las mismas.
CL2016002798A1 (es) Compuestos derivados de triciclos nitrogenados que contienen una naftiridina condensada con un bencimidazol y su uso como inhibidores de la proliferación celular para el tratamiento del cáncer de pulmón, colorrectal, hígado, páncreas, ganglio linfático, colon, próstata, cerebro, cabeza y cuello, piel, riñón sangre o corazón.
MX2016006726A (es) Composiciones que comprenden anticuerpos anti-molecula de adhesion celular relacionada con antigeno carcinoembrionario 1 y anti-muerte celular programada para la terapia contra el cancer.
CO2017007121A2 (es) Compuestos bicíclicos fusionados para el tratamiento de enfermedades
EP3781188A4 (en) ADOPTIVE CELL THERAPY
CL2021002318A1 (es) Métodos de tratamiento de amiloidosis al
MX2018007818A (es) Anticuerpos dirigidos contra upk1b novedosos y metodos para su uso.
MX386249B (es) Terapia tusc2 para usarse en el tratamiento de cáncer.